A Phase 4 interventional study of atorvastatin and amlodipine in Hypertension and Hyperlipidemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing atorvastatin in Hypertension — 1 open to participants now, 2 under way, none of them phase 3. Atorvastatin · Hypertension.
Among the 19 studies testing atorvastatin in Hypertension, this one is the 5th largest by enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 2nd registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 19 studies testing atorvastatin in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 88 across the 19 interventional studies. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
34 studies in Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 34 finished, 11 (32%) have results posted.
Among the 34 studies in Hypertension by Viatris Inc., this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2005, is one of 11 in phase 4, and was the 11th registered.
Viatris Inc.’s Hypertension studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing atorvastatin in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 34 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone
To provide comparative evaluation of the safety profile of the dual therapy with atorvastatin + amlodipine versus amlodipine alone.
The record gives a start of May 2005 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Amlodipine
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →